EPIPEN- epinephrine injection 
Asclemed USA, Inc.

----------

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use EPIPEN ®safely and effectively. See full prescribing information for EPIPEN.

EPIPEN ®(epinephrine injection), for intramuscular or subcutaneous use

Initial U.S. Approval: 1939

INDICATIONS AND USAGE

EpiPen are non-selective alpha and beta-adrenergic receptor agonist indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis. ( 1)

DOSAGE AND ADMINISTRATION

  • Patients greater than or equal to 30 kg (66 lbs): EpiPen 0.3 mg ( 2)

Inject intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary. Each device is a single-dose injection .( 2)

DOSAGE FORMS AND STRENGTHS

  • Injection: 0.3 mg (0.3 mg/0.3 mL) single-dose pre-filled auto-injector ( 3)

CONTRAINDICATIONS

None ( 4)

WARNINGS AND PRECAUTIONS

  • In conjunction with use, seek immediate medical or hospital care. ( 5.1)
  • Do not inject intravenously, into buttock, or into digits, hands, or feet. ( 5.2)
  • To minimize the risk of injection related injury, hold the child’s leg firmly in place and limit movement prior to and during injection when administering to young children. ( 5.2)
  • Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop signs or symptoms of infection. ( 5.3)
  • The presence of a sulfite in this product should not deter use. ( 5.4)
  • Administer with caution in patients with heart disease; may aggravate angina pectoris or produce ventricular arrhythmias. ( 5.5)

ADVERSE REACTIONS

Adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties. ( 6)

To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Cardiac glycosides or diuretics: observe for development of cardiac arrhythmias. ( 7)
  • Tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines potentiate effects of epinephrine. ( 7)
  • Beta-adrenergic blocking drugs antagonize cardiostimulating and bronchodilating effects of epinephrine. ( 7)
  • Alpha-adrenergic blocking drugs antagonize vasoconstricting and hypertensive effects of epinephrine. ( 7)
  • Ergot alkaloids may reverse the pressor effects of epinephrine. ( 7)

USE IN SPECIFIC POPULATIONS

  • Elderly patients may be at greater risk of developing adverse reactions. ( 5.5, 8.5)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 8/2023

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage According to Patient Body Weight

2.2 Administration Instructions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Emergency Treatment

5.2 Injection-Related Complications

5.3 Serious Infections at the Injection Site

5.4 Allergic Reactions Associated with Sulfite

5.5 Disease Interactions

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*
Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

EpiPen are indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. EpiPen are intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Anaphylactic reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria or angioedema. EpiPen are intended for immediate administration as emergency supportive therapy only and are not a substitute for immediate medical care.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage According to Patient Body Weight

  • Patients greater than or equal to 30 kg (approximately 66 pounds or more): EpiPen 0.3 mg

2.2 Administration Instructions

  • Inject the single-dose EpiPen intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary. Do not inject intravenously, and do not inject into buttocks, into digits, hands or feet [see Warnings and Precautions (5.2)].
  • Instruct caregivers of young children who are prescribed an EpiPen and who may be uncooperative and kick or move during an injection to hold the leg firmly in place and limit movement prior to and during an injection [see Warnings and Precautions (5.2)] .
  • Each EpiPen is a single-dose epinephrine injection for single use. Since the doses of epinephrine delivered from EpiPen are fixed, consider using other forms of injectable epinephrine if doses lower than 0.15 mg are deemed necessary.
  • With severe persistent anaphylaxis, repeat injections with an additional EpiPen may be necessary. More than two sequential doses of epinephrine should only be administered under direct medical supervision [see Warnings and Precautions (5.1)] .
  • The epinephrine solution in the clear window of the EpiPen Auto-Injector should be inspected visually for particulate matter and discoloration.

Discarding After Use:

The EpiPen each contain 2 mL epinephrine solution. Approximately 1.7 mL remains in the auto-injector after activation, but is not available for future use, and should be discarded .

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

None

5 WARNINGS AND PRECAUTIONS

5.1 Emergency Treatment

EpiPen are intended for immediate administration as emergency supportive therapy and are not intended as a substitute for immediate medical care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. More than two sequential doses of epinephrine should only be administered under direct medical supervision [ see Indications and Usage (1), Dosage and Administration (2)and Patient Counseling Information (17)].

5.2 Injection-Related Complications

EpiPen should onlybe injected into the anterolateral aspect of the thigh [ see Dosage and Administration (2)and Patient Counseling Information (17)].

Do not inject intravenously

Large doses or accidental intravenous injection of epinephrine may result in cerebral hemorrhage due to sharp rise in blood pressure. Rapidly acting vasodilators can counteract the marked pressor effects of epinephrine if there is such inadvertent administration.

Do not inject into buttock

Injection into the buttock may not provide effective treatment of anaphylaxis. Advise the patient to go immediately to the nearest emergency room for further treatment of anaphylaxis. Additionally, injection into the buttock has been associated with Clostridial infections (gas gangrene). Cleansing with alcohol does not kill bacterial spores, and therefore, does not lower this risk.

Do not inject into digits, hands or feet

Since epinephrine is a strong vasoconstrictor, accidental injection into the digits, hands or feet may result in loss of blood flow to the affected area. Advise the patient to go immediately to the nearest emergency room and to inform the healthcare provider in the emergency room of the location of the accidental injection. Treatment of such inadvertent administration should consist of vasodilation, in addition to further appropriate treatment of anaphylaxis [ see Adverse Reactions (6)].

Hold leg firmly during injection

Lacerations, bent needles, and embedded needles have been reported when EpiPen have been injected into the thigh of young children who are uncooperative and kick or move during an injection. To minimize the risk of injection related injury when administering, hold the child’s leg firmly in place and limit movement prior to and during injection.

5.3 Serious Infections at the Injection Site

Rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported at the injection site following epinephrine injection for anaphylaxis. Clostridiumspores can be present on the skin and introduced into the deep tissue with subcutaneous or intramuscular injection. While cleansing with alcohol may reduce presence of bacteria on the skin, alcohol cleansing does not kill Clostridiumspores. To decrease the risk of Clostridiuminfection, do not inject EpiPen into the buttock [see Warnings and Precautions (5.2)]. Advise patients to seek medical care if they develop signs or symptoms of infection, such as persistent redness, warmth, swelling, or tenderness, at the epinephrine injection site.

5.4 Allergic Reactions Associated with Sulfite

The presence of a sulfite in this product should not deter administration of the drug for treatment of serious allergic or other emergency situations even if the patient is sulfite-sensitive.

Epinephrine is the preferred treatment for serious allergic reactions or other emergency situations even though this product contains sodium metabisulfite, a sulfite that may, in other products, cause allergic-type reactions including anaphylactic symptoms or life-threatening or less severe asthmatic episodes in certain susceptible persons.

The alternatives to using epinephrine in a life-threatening situation may not be satisfactory.

5.5 Disease Interactions

Some patients may be at greater risk for developing adverse reactions after epinephrine administration. Despite these concerns, it should be recognized that the presence of these conditions is not a contraindication to epinephrine administration in an acute, life-threatening situation. Therefore, patients with these conditions, and/or any other person who might be in a position to administer EpiPen to a patient experiencing anaphylaxis should be carefully instructed in regard to the circumstances under which epinephrine should be used.

Patients with Heart Disease

Epinephrine should be administered with caution to patients who have heart disease, including patients with cardiac arrhythmias, coronary artery or organic heart disease, or hypertension .In such patients, or in patients who are on drugs that may sensitize the heart to arrhythmias ,epinephrine may precipitate or aggravate angina pectoris as well as produce ventricular arrhythmias [ see Drug Interactions (7)and Adverse Reactions (6)].

Other Patients and Diseases

Epinephrine should be administered with caution to patients with hyperthyroidism, diabetes, elderly individuals, and pregnant women. Patients with Parkinson’s disease may notice a temporary worsening of symptoms.

6 ADVERSE REACTIONS

Due to the lack of randomized, controlled clinical trials of epinephrine for the treatment of anaphylaxis, the true incidence of adverse reactions associated with the systemic use of epinephrine is difficult to determine. Adverse reactions reported in observational trials, case reports, and studies are listed below.

Common adverse reactions to systemically administered epinephrine include anxiety; apprehensiveness; restlessness; tremor; weakness; dizziness; sweating; palpitations; pallor; nausea and vomiting; headache; and/or respiratory difficulties. These symptoms occur in some persons receiving therapeutic doses of epinephrine, but are more likely to occur in patients with hypertension or hyperthyroidism [ see Warnings and Precautions (5.5)].

Cardiovascular Reactions

Reactions from Accidental Injection and/or Improper Technique

Skin and Soft Tissue Infections

7 DRUG INTERACTIONS

Cardiac Glycosides, Diuretics, and Anti-arrhythmics

Patients who receive epinephrine while concomitantly taking cardiac glycosides, diuretics, or anti-arrhythmics should be observed carefully for the development of cardiac arrhythmias [see Warnings and Precautions (5.5)] .

Antidepressants, Monoamine Oxidase Inhibitors, Levothyroxine, and Antihistamines

The effects of epinephrine may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine.

Beta-Adrenergic Blockers

The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta- adrenergic blocking drugs, such as propranolol.

Alpha-Adrenergic Blockers

The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha- adrenergic blocking drugs, such as phentolamine.

Ergot Alkaloids

Ergot alkaloids may also reverse the pressor effects of epinephrine.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no adequate and well controlled studies of the acute effect of epinephrine in pregnant women. In animal reproductive studies, epinephrine administered by the subcutaneous route to rabbits, mice, and hamsters during the period of organogenesis was teratogenic at doses 7 times and higher than the maximum recommended human intramuscular and subcutaneous dose on a mg/m 2basis. Epinephrine is the first-line medication of choice for the treatment of anaphylaxis during pregnancy in humans. Epinephrine should be used for treatment of anaphylaxis during pregnancy in the same manner as it is used in non-pregnant patients.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations

Disease-associated maternal and embryo/fetal risk

During pregnancy, anaphylaxis can be catastrophic and can lead to hypoxic-ischemic encephalopathy and permanent central nervous system damage or death in the mother and, more commonly, in the fetus or neonate. The prevalence of anaphylaxis occurring during pregnancy is reported to be approximately 3 cases per 100,000 deliveries.

Management of anaphylaxis during pregnancy is similar to management in the general population. Epinephrine is the first line-medication of choice for treatment of anaphylaxis; it should be used in the same manner in pregnant and non-pregnant patients. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care.

Data

Animal Data

In an embryofetal development study with rabbits dosed during the period of organogenesis, epinephrine was shown to be teratogenic (including gastroschisis and embryonic lethality) at doses approximately 40 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2basis at a maternal subcutaneous dose of 1.2 mg/kg/day for two to three days).

In an embryofetal development study with mice dosed during the period of organogenesis, epinephrine was shown to be teratogenic (including embryonic lethality) at doses approximately 8 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2basis at maternal subcutaneous dose of 1 mg/kg/day for 10 days). These effects were not seen in mice at approximately 4 times the maximum recommended daily intramuscular or subcutaneous dose (on a mg/m 2basis at a subcutaneous maternal dose of 0.5 mg/kg/day for 10 days).

In an embryofetal development study with hamsters dosed during the period of organogenesis from gestation days 7 to 10, epinephrine was shown to be teratogenic at doses approximately 7 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2basis at a maternal subcutaneous dose of 0.5 mg/kg/day).

8.2 Lactation

Risk Summary

There is no information on the presence of epinephrine in human milk, the effects on breastfed infants, or the effects on milk production. Epinephrine is the first line-medication of choice for treatment of anaphylaxis; it should be used in the same manner in breastfeeding and non-breastfeeding patients.

8.4 Pediatric Use

EpiPen may be administered to pediatric patients at a dosage appropriate to body weight [ see Dosage and Administration (2.1)] .Clinical experience with the use of epinephrine suggests that the adverse reactions seen in children are similar in nature and extent to those both expected and reported in adults. Since the doses of epinephrine delivered from EpiPen are fixed, consider using other forms of injectable epinephrine if doses lower than 0.15 mg are deemed necessary.

8.5 Geriatric Use

Clinical studies for the treatment of anaphylaxis have not been performed in subjects aged 65 and over to determine whether they respond differently from younger subjects. However, other reported clinical experience with use of epinephrine for the treatment of anaphylaxis has identified that geriatric patients may be particularly sensitive to the effects of epinephrine. Therefore, EpiPen should be administered with caution in elderly individuals, who may be at greater risk for developing adverse reactions after epinephrine administration [ see Warnings and Precautions (5.5), Overdosage (10)].

10 OVERDOSAGE

Overdosage of epinephrine may produce extremely elevated arterial pressure, which may result in cerebrovascular hemorrhage, particularly in elderly patients. Overdosage may also result in pulmonary edema because of peripheral vascular constriction together with cardiac stimulation. Treatment consists of rapidly acting vasodilators or alpha-adrenergic blocking drugs and/or respiratory support.

Epinephrine overdosage can also cause transient bradycardia followed by tachycardia, and these may be accompanied by potentially fatal cardiac arrhythmias. Premature ventricular contractions may appear within one minute after injection and may be followed by multifocal ventricular tachycardia (prefibrillation rhythm). Subsidence of the ventricular effects may be followed by atrial tachycardia and occasionally by atrioventricular block. Treatment of arrhythmias consists of administration of a beta-adrenergic blocking drug such as propranolol.

Overdosage sometimes results in extreme pallor and coldness of the skin, metabolic acidosis, and kidney failure. Suitable corrective measures must be taken in such situations.

11 DESCRIPTION

EpiPen (epinephrine injection, USP) 0.3 mg are single-dose auto-injectors and combination products containing drug and device components.

Each EpiPen Auto-Injector, 0.3 mg delivers a single dose of 0.3 mg epinephrine from epinephrine injection, USP 0.3 mg/0.3 mL in a sterile solution.

Each 0.3 mL in the EpiPen Auto-Injector contains 0.3 mg epinephrine, 1.8 mg sodium chloride, 0.5 mg sodium metabisulfite, hydrochloric acid to adjust pH, and Water for Injection. The pH range is 2.2-5.0.

Epinephrine is a sympathomimetic catecholamine. Chemically, epinephrine is (-)-3,4- Dihydroxy-α-[(methylamino)methyl]benzyl alcohol with the following structure:

Epinephrine Structural Formula

Epinephrine solution deteriorates rapidly on exposure to air or light, turning pink from oxidation to adrenochrome and brown from the formation of melanin. Replace EpiPen if the epinephrine solution appears discolored (pinkish or brown color), cloudy, or contains particles.

Thoroughly review the patient instructions and operation of EpiPen with patients and caregivers prior to use [ see Patient Counseling Information (17)].

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Epinephrine acts on both alpha- and beta-adrenergic receptors.

12.2 Pharmacodynamics

Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension.

Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing and dyspnea that may occur during anaphylaxis.

Epinephrine also alleviates pruritus, urticaria, and angioedema and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder.

When given subcutaneously or intramuscularly, epinephrine has a rapid onset and short duration of action.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies to evaluate the carcinogenic potential of epinephrine have not been conducted.

Epinephrine and other catecholamines have been shown to have mutagenic potential in vitro. Epinephrine was positive in the Salmonellabacterial reverse mutation assay, positive in the mouse lymphoma assay, and negative in the in vivomicronucleus assay. Epinephrine is an oxidative mutagen based on the E. coliWP2 Mutoxitest bacterial reverse mutation assay. This should not prevent the use of epinephrine where indicated [see Indications and Usage (1)].

The potential for epinephrine to impair reproductive performance has not been evaluated, but epinephrine has been shown to decrease implantation in female rabbits dosed subcutaneously with 1.2 mg/kg/day (40-fold the highest human intramuscular or subcutaneous daily dose) during gestation days 3 to 9.

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

EpiPen 2-Pak ®also include an S-clip to clip two carrier tubes together.

Storage and Handling

17 PATIENT COUNSELING INFORMATION

See FDA-Approved Patient Labeling ( Patient Information and Instructions for Use)

A healthcare provider should review the patient instructions and operation of EpiPen in detail, with the patient or caregiver.

Epinephrine is essential for the treatment of anaphylaxis. Patients who are at risk of or with a history of severe allergic reactions (anaphylaxis) to insect stings or bites, foods, drugs, and other allergens, as well as idiopathic and exercise-induced anaphylaxis, should be carefully instructed about the circumstances under which epinephrine should be used.

Administration

Instruct patients and/or caregivers in the appropriate use of EpiPen. EpiPen should be injected into the middle of the outer thigh (through clothing, if necessary). Each device is a single-use injection. Advise patients to seek immediate medical care in conjunction with administration of EpiPen.

Instruct caregivers to hold the leg of young children firmly in place and limit movement prior to and during injection. Lacerations, bent needles, and embedded needles have been reported when EpiPen have been injected into the thigh of young children who are uncooperative and kick or move during an injection [ see Warnings and Precautions (5.2)].

Instruct patients and/or caregivers to throw away the blue safety release immediately after using EpiPen. This small part may pose a choking hazard for children.

Complete patient information, including dosage, directions for proper administration and precautions can be found inside each EpiPen  carton. A printed label on the surface of EpiPen shows instructions for use and a diagram depicting the injection process.

Training

Instruct patients and/or caregivers to use and practice with the Trainer to familiarize themselves with the use of EpiPen in an allergic emergency. The Trainer may be used multiple times. A Trainer device is provided in 2-Pak cartons.

Instruct patients and/or caregivers to immediately place the blue safety release back on the Trainer and reset it after practicing. This small part may pose a choking hazard for children.

Adverse Reactions

Epinephrine may produce symptoms and signs that include an increase in heart rate, the sensation of a more forceful heartbeat, palpitations, sweating, nausea and vomiting, difficulty breathing, pallor, dizziness, weakness or shakiness, headache, apprehension, nervousness, or anxiety. These signs and symptoms usually subside rapidly, especially with rest, quiet and recumbency. Patients with hypertension or hyperthyroidism may develop more severe or persistent effects, and patients with coronary artery disease could experience angina. Patients with diabetes may develop increased blood glucose levels following epinephrine administration. Patients with Parkinson’s disease may notice a temporary worsening of symptoms [ see Warnings and Precautions (5.5)] .

Accidental Injection

Advise patients to seek immediate medical care in the case of accidental injection. Since epinephrine is a strong vasoconstrictor when injected into the digits, hands, or feet, treatment should be directed at vasodilatation if there is such an accidental injection to these areas [ see Warnings and Precautions (5.2)].

Serious Infections at the Injection Site

Rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported at the injection site following epinephrine injection for anaphylaxis. Advise patients to seek medical care if they develop signs or symptoms of infection, such as persistent redness, warmth, swelling, or tenderness, at the epinephrine injection site [ see Warnings and Precautions (5.3)].

Storage and Handling

Instruct patients to inspect the epinephrine solution visually through the clear window of the auto-injector periodically. Replace EpiPen if the epinephrine solution appears discolored (pinkish or brown color), cloudy, or contains particles. Epinephrine is light sensitive and should be stored in the carrier tube provided to protect it from light. The carrier tube is not waterproof. Instruct patients that EpiPen must be used or properly disposed once the blue safety release is removed or after use [ see Storage and Handling (16.2)].

Advise patients and caregivers to give used EpiPen auto-injectors to their healthcare provider for inspection and proper disposal.

Advise patients and caregivers to promptly dispose of medicines that are no longer needed. Dispose of expired, unwanted, or unused EpiPen auto-injectors in an FDA-cleared sharps container. Instruct patients not to dispose EpiPen in their household trash. Instruct patients that if they do not have a FDA-cleared sharps disposal container, they may use a household container that is made of a heavy-duty plastic, can be closed with a tight-fitting and puncture-resistant lid without sharps being able to come out, upright and stable during use, leak-resistant, and properly labeled to warn of hazardous waste inside the container. Inform patients that they can visit the FDA website for additional information on disposal of unused medicines.

Complete patient information, including dosage, directions for proper administration and precautions can be found inside each EpiPen Auto-Injector carton.

Relabeled by:

Enovachem PHARMACEUTICALS

Torrance, CA 90501

PATIENT INFORMATION and INSTRUCTIONS FOR USE

EPIPEN ®[/epeepen/]
(epinephrine injection, USP) Auto-Injector 0.3 mg
EpiPen ®= one dose of 0.3 mg epinephrine, USP 0.3 mg/0.3 mL

For allergic emergencies (anaphylaxis)

PATIENT INFORMATION

Read this Patient Information leaflet carefully before using the EpiPen ®auto-injector and each time you get a refill. There may be new information. Anyone who may be able to administer the EpiPen auto-injector should know how to use it before you have an allergic emergency.

This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.

What is the most important information I should know about EpiPen?

  1. EpiPen are single-dose automatic injection devices (auto-injectors) that contain epinephrine. Epinephrine is a medicine used to treat allergic emergencies (anaphylaxis). Anaphylaxis can be life threatening and can happen within minutes. If untreated, anaphylaxis can lead to death. This allergic emergency can be caused by stinging and biting insects, allergy injections, foods, medicines, exercise, or unknown causes.

Symptoms of anaphylaxis may include:

2. Always carry 2 EpiPen auto-injectorswith you because sometimes a single dose of epinephrine may not be enough to treat a serious allergic reaction before seeking medical care. You also need to always carry 2 auto-injectors with you if the first auto-injector is activated before the dose can be given. A device that has been activated by accident cannot be used in an allergic emergency (anaphylaxis).


Note: The EpiPen auto-injector has been activated when the blue safety top is removed and a “pop” is heard, the orange needle end of the auto-injector is extended, or the medicine viewing window is blocked.

You may not know when anaphylaxis will happen. Talk to your healthcare provider if you need more auto-injectors to keep at work, school, or other locations. If you use 1 EpiPen 1 to treat an emergency allergic reaction, be sure to replace it so you always carry 2 auto-injectors. Tell your family members, caregivers, and others where you keep your EpiPen auto-injectors. Make sure they know how to use it before you need it. You may be unable to speak in an allergic emergency.

3. When you have an allergic emergency (anaphylaxis) use your EpiPen auto-injector right away.Get emergency medical help right away even if you have used the EpiPen auto-injector. You can use a second EpiPen auto-injector if symptoms continue or come back or if the first auto-injector is activated before the dose can be given. For this reason, you should carry 2 EpiPen auto-injectors with you at all times. If you need more than 2 doses for an allergic emergency, they must be given by a healthcare provider.

What are EpiPen auto-injectors?

What should I tell my healthcare provider before using EpiPen ?

Before you use your EpiPen auto-injector, tell your healthcare provider about all your medical conditions. Your healthcare provider may give you more instructions about when and how to use EpiPen if you have the following:

You may also receive more instructions if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Tell your healthcare provider about all of your known allergies.

Especially tell your healthcare provider if you take certain asthma medicines.

EpiPen other medicines may affect each other, causing side effects. EpiPen may affect the way other medicines work. Other medicines may affect how EpiPen works.

Know the medicines you take. Keep a list of all your medicines, including over-the-counter medicines, vitamins and herbal supplements to show your healthcare provider and pharmacist when you get a new medicine.

Use your EpiPen auto-injector for treatment of anaphylaxis as prescribed by your healthcare provider, regardless of your medical conditions or the medicines you take.

How should I use the EpiPen auto-injector?

What are the possible side effects of EpiPen ?

EpiPen may cause serious side effects.

If you accidentally inject EpiPen into any place other than the middle of your outer thigh, go to the nearest emergency room right away. Tell the healthcare provider where on your body you received the accidental injection.

     1. Hold the young child firmly in place (restrain).

     2. With one hand, grip the auto-injector with the orange needle end pointing down.

     3. With the other hand, pull the blue safety top straight up and away from the auto-injector.

Common side effects of EpiPen include:

These side effects may go away with rest. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of EpiPen . For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store EpiPen auto-injectors?

Disposing of an Expired, Unused or Used EpiPen Auto-Injector

Your EpiPen auto-injector has an expiration date. Replace the pack of auto-injectors before the expiration date. Throw away (dispose of) expired, unwanted, or unused EpiPen auto-injectors in an FDA-cleared sharps disposal container right away after use. Do not throw away the EpiPen in your household trash. If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:

When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal

Visit the FDA’s website (https://www.fda.gov/drugs/safe-disposal-medicines/disposal-unused-medicines-what-you-should-know) for more information about how to throw away unused, unwanted or expired medicines.

After using your EpiPen auto-injector in an allergic emergency, get emergency medical help right away. Take your used EpiPen auto-injector with you to give to your healthcare provider for disposal.

General information about the safe and effective use of EpiPen auto-injectors.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use the EpiPen auto-injector for a condition for which it was not prescribed. Do not give your EpiPen auto-injector to other people.

This Patient Information leaflet summarizes the most important information about the EpiPen auto-injectors. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about EpiPen auto-injectors that is written for health professionals.

What are the ingredients in EpiPen ?

Active Ingredients: epinephrine

Inactive Ingredients: sodium chloride, sodium metabisulfite, hydrochloric acid, and water

Important Information

Incorrect Use

Correct Use and

Important Reminders

Storage outside the protective case or storage of the EpiPen auto-injector in extreme cold or heat.

Always keep your EpiPen stored in the protective case and at room temperature. Keep protective case in the outer carton to protect from light. Wrong storage may stop the EpiPen from working. If the device has been in extreme cold or heat, the EpiPen should be replaced.

Failing to remove the auto-injector from the protective case before use.

The EpiPen auto-injector must be removed from the protective case it comes in before use.

Failing to remove the blue safety top before use.

Remove the blue safety top before use. EpiPen will not activate with the blue safety top in place.

Activating the auto-injector upside down which will cause an injection into the hand.

The needle exits from the orange end of the EpiPen auto-injector, which should be in contact with the outer thigh (upper leg) at a 90˚angle (perpendicular) to the thigh before and during activation. The orange needle end will extend to cover the needle after activation. If you can still see the needle, do not try to reuse the auto-injector.

Failing to apply enough force to activate the EpiPen auto-injector.

EpiPen should be administered by swinging and pushing the auto-injector firmly against the outer thigh. EpiPen auto-injectors make a distinct pop sound when pushed against the thigh. The pop sound signals that the injection has started. The correct dose has been administered if the orange needle end is extended and the window is blocked.

Administering at an injection site other than the outer thigh.

Administer EpiPen in the outer thigh only.

Failing to hold the auto-injector in place for a full 3 seconds.

Hold the EpiPen auto-injector in place for a full 3 seconds following activation (count slowly 1, 2, 3).

For more information and video instructions on the use of EpiPen auto-injectors, go to www.epipen.comor call 1-800-395-3376.

INSTRUCTIONS FOR USE

EPIPEN ® [/epeepen/]
(epinephrine injection, USP) Auto-Injector 0.3 mg
EpiPen ®= one dose of 0.3 mg epinephrine,
USP 0.3 mg/0.3 mL
for intramuscular and subcutaneous use

This Instructions for Use contains information on how to administer the EpiPen auto-injector.

Figure A. Single 0.3 mg dose, EpiPen auto-injector (with yellow label) and Single 0.15 mg dose, EpiPen Jr auto-injector (with green label)

Figure A. Single 0.3 mg dose, EpiPen auto-injector (with yellow label)

Important Information You Need to Know Before Administering the EpiPen Auto-Injector

Figure B. Inject into middle of the outer thigh

Figure B. Inject into middle of the outer thigh

Figure C. Correct way to hold the EpiPen auto-injector with orange needle end pointing down

Figure C. Correct way to hold the EpiPen auto-injector with orange needle end pointing down

Checking the Blue Safety Top

When receiving an EpiPen auto-injector and before you need to use the EpiPen auto-injector, do the following:

Patient Information Figures D and E

Preparing to Inject EpiPen

Note the following while preparing to inject EpiPen :

Figure F. Gray Trainer

Figure F. Gray Trainer

Figure G. Never-See-Needle

Figure G. Never-See-Needle

Figure G. Never-See-Needle

Make sure the EpiPen auto-injector has notbeen used. If an EpiPen auto-injector has been used:

Preparing to Inject a Child


Checking the Medicine Color

Examine the liquid in the medicine viewing window of your EpiPen auto-injector regularly. See the information below:

Patient Information Medicine Color

Medicine Color:

  • The medicine can be seen through the medicine viewing window located near the middle of the EpiPen auto-injector.
To check the medicine color, hold the auto-injector in front of a white background in a well-lit area and look through the medicine viewing window.

Figure H. Medicine Viewing Window

✓Use the medicine if it is clear and colorless.

Do not use the medicine if it is discolored (pinkish or brown color) or if the medicine has particles floating in it. Throw it away (dispose of) and use a new EpiPen auto-injector (see the section “ Disposing of an Expired, Unused or Used EpiPen Auto-Injector” on the Patient Information side of this leaflet).

Injecting EpiPen

Step 1    Slide the EpiPen auto-injector out of the case (Figure I)

Remove the auto-injector from the protective case.

Patient Information Figure I

Figure I.

Step 2    Pull off the blue safety top (Figure J)

Grip the EpiPen auto-injector with one hand and with the orange needle end pointing down. Use the other hand to remove the blue safety top. Pull it straight up and away .

Patient Information Figure J

Figure J.

Note:Do not twist or bend the blue safety top. Failure to pull out the blue safety top correctly (straight up and away) can cause accidental activation.

Note:To avoid an accidental injection, never put your thumb, fingers or hand over the orange needle end. If an accidental injection happens, get emergency medical help right away.

Step 3    Inject the medicine by self (Figure K) or caregiver (Figure L) administration

Place the orange needle end against the outer thigh, through clothing if needed.

Push down firmly and hold in place for 3 seconds.

Note:EpiPen auto-injectors make a distinct pop sound when pushed against the thigh. This is normal and means that the EpiPen auto-injector is working. After the pop, continue to press the EpiPen auto-injector down firmly on the outer thigh for 3 seconds to make sure that the medicine is given.

Patient Information Figure K

Figure K.

Patient Information Figure L

Figure L.

Step 4    Check if used (Figure M)

Lift the auto-injector straight out from the thigh.

The orange needle end will extend to cover the needle. If the needle is visible, do not reuse it. Use a new auto-injector.

Throw away the blue safety top.

Patient Information Figure M

Figure M.

Step 5    Get emergency medical help

After injecting EpiPen , get emergency medical help right away. You can use a second EpiPen auto-injector if symptoms continue or come back.

  • Take your used EpiPen auto-injector to your healthcare provider.
  • EpiPen are single-dose auto-injectors and cannot be reused.
  • If the needle is visible, do not try to reuse it.

Storing EpiPen Auto-Injectors

Store the EpiPen auto-injectors at room temperature between 68˚ F to 77˚ F (20˚ C to 25˚ C).

Keep protective case in the outer carton to protect from light. When exposed to air or light, the medicine in the EpiPen auto-injector changes rapidly to a pinkish or brown color and should not be used.

Disposing of EpiPen Auto-Injectors

After using your EpiPen auto-injector, get emergency medical help right away. Take your used auto-injector with you to give to your healthcare provider for disposal.

Important:The blue safety top is a small part that may become a choking hazard for children. Throw away the blue safety top immediately after using the EpiPen auto-injector.

Your EpiPen auto-injector has an expiration date. Replace it before the expiration date.

For more information on how to throw away (dispose of) your expired EpiPen auto-injector, see the section “ Disposing of an Expired, Unused or Used EpiPen Auto-Injector” on the Patient Information side of this leaflet.

Relabeled by:

Enovachem PHARMACEUTICALS

Torrance, CA 90501

EPIPEN ®
(epinephrine injection, USP) Auto-Injector 0.3 mg
EpiPen ®= one dose of 0.3 mg epinephrine, USP 0.3 mg/0.3 mL

For more information about EpiPen auto-injectors and proper use of the product, call Mylan at 1-877-446-3679 or visit www.epipen.comfor an instructional video.

EpiPen Trainer Instructions for Use

In an emergency: Do not use the gray Trainer. Use your real yellow EpiPen® auto-injector. 

Important Information

The EpiPen Trainer

Familiarize yourself with this gray Trainer. Practice until you are comfortable using it.

Your gray Trainer:

Figure A. Your Gray Trainer

Figure A. Your Gray Trainer

Figure A. Your Gray Trainer

Caution: Know the difference between the Trainer and your real yellow EpiPen Auto-Injector

Important differences between the Trainer and your real yellow EpiPen auto-injector

Trainer

EpiPen

Trainer (Gray)

EpiPen (Yellow)

Contains medicine?

No

Yes

Has needle?

No

Yes

Comes in Protective Case?

No

Yes

Color of Label?

Gray

Yellow

Has expiration date?

No

Yes

Can be reused?

Yes

No(use only one time)

Okay to remove and replace blue safety top?

Yes

No(remove just one time before use)

Pressure needed to hold against thigh?

Moderate

Strong

Practice Instructions

Using the Trainer

Step 1    Pull off the blue safety top (Figure B)

Grip the gray Trainer with one hand and with the orange end pointing down. Use the other hand to remove the blue safety top. Pull it straight up and away. Note:Do not twist or bend the blue safety top.

Warning: Do notflip the blue safety top off using a thumb or by pulling it sideways or by bending and twisting the blue safety top. This may cause the real yellow EpiPen auto-injector to accidentally activate. An EpiPen auto-injector that has been activated by accident cannot be used for a patient in an emergency and must be replaced.

Practice Instructions Figure B

Figure B

Step 2    Trainer injection simulation by self (Figure C) or caregiver (Figure D) administration

Place the orange end against the outer thigh, over clothing if needed.


Push down firmly and hold in place for 3 seconds. If practicing an injection on a young child, first hold the child firmly (restrain) and then use one hand to hold the Trainer with the orange end pointing down and your other hand to remove the blue safety top. Hold the leg firmly in place before and during the 3 second practice injection to prevent injuries.

Note:The Trainer makes a distinct pop sound when pushed against the thigh. This is normal and means that the auto-injector is working. After the pop, continue to press the Trainer down firmly on the outer thigh for 3 seconds.

Practice Instructions Figure C

Figure C

Practice Instructions Figure D

Figure D

Step 3    Check if used (Figure E)

Lift the Trainer straight out from the thigh. Inspect: The Trainer was activated correctly if the orange end is extended. If the orange end is not extended, repeat Step 1 and Step 2.

Practice Instructions Figure E

Figure E

Step 4    Reset the Trainer (Figure F)

Put the blue safety top back on the Trainer immediately. Place the orange end on a hard surface. Squeeze the sides of the orange end and push down on the Trainer with the other hand. Note:This resetting step should never be used with a real yellow EpiPen auto-injector as this may result in injury.

Never put your thumb, other fingers, or hand over the orange (needle) end of the real yellow EpiPen auto-injector.

Practice Instructions Figure F

Figure F

Practice Session Information

In case of an allergic emergency, use the real yellow EpiPen auto-injector and not the gray Trainer.

Follow instructions above. Repeat as often as needed until you are able to inject quickly and correctly. Regularly practice with the Trainer to make sure that you are able to use the real yellow EpiPen auto-injector in an emergency situation.

Reread:

Train others who could help you in an emergency:

For more information about the EpiPen auto-injector and the proper use of the products, go to www.epipen.com.

Relabeled by:

Enovachem PHARMACEUTICALS

Torrance, CA 90501

PRINCIPAL DISPLAY PANEL

Label
EPIPEN 
epinephrine injection
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:76420-584(NDC:49502-500)
Route of AdministrationINTRAMUSCULAR
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
EPINEPHRINE (UNII: YKH834O4BH) (EPINEPHRINE - UNII:YKH834O4BH) EPINEPHRINE0.3 mg  in 0.3 mL
Inactive Ingredients
Ingredient NameStrength
SODIUM CHLORIDE (UNII: 451W47IQ8X)  
SODIUM METABISULFITE (UNII: 4VON5FNS3C)  
HYDROCHLORIC ACID (UNII: QTT17582CB)  
WATER (UNII: 059QF0KO0R)  
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:76420-584-022 in 1 CARTON08/29/2023
11 in 1 CONTAINER
10.3 mL in 1 SYRINGE, GLASS; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA01943012/22/1987
Labeler - Asclemed USA, Inc. (059888437)
Establishment
NameAddressID/FEIBusiness Operations
ASCLEMED USA INC. DBA ENOVACHEM059888437relabel(76420-584)

Revised: 8/2023
Document Id: 040d1b88-235a-aa09-e063-6394a90adbad
Set id: 311af6d9-20c0-4b87-b236-4185bfa49988
Version: 1
Effective Time: 20230829
 
Asclemed USA, Inc.